Cardiology · Coronary Artery Disease
Stable Ischemic Heart Disease
Managing Chronic Angina — Anti-Anginal Therapy, Stress Testing, and the Medical Therapy Primacy Established by COURAGE and ISCHEMIA
Stable ischemic heart disease (SIHD) is the condition in which fixed or dynamic coronary obstruction produces predictable, exertional chest discomfort that is relieved by rest or nitroglycerin within minutes. The defining clinical signature is reproducibility: the same walk, the same flight of stairs, the same angina. What separates stable angina from an acute coronary syndrome is not the coronary anatomy but the absence of plaque rupture, thrombus, and dynamic flow obstruction. In the United States, roughly 9 million people carry a diagnosis of stable angina, and the condition accounts for hundreds of thousands of outpatient visits per year.[1] The management question that dominated cardiology for thirty years — when to open the artery versus when to optimize medications — has now been answered twice by large randomized trials. For most patients with stable angina, even those with significant ischemia on stress testing, a strategy of maximizing anti-anginal and cardioprotective medications is not inferior to proceeding directly to revascularization for preventing death or myocardial infarction. That evidence base changes how this condition must be explained to patients and how their escalating symptoms should be interpreted and acted upon.
William Heberden described angina pectoris before the Royal College of Physicians in 1768 with a clinical precision that has barely been improved upon. He noted the strangling pressure in the chest, its reliable onset with walking (especially uphill or after a meal), and its equally reliable resolution with rest. He observed patients over years and noted that several died suddenly while engaged in ordinary tasks. He had no theory for the cause. He was simply watching and reporting. His clinical description — the exertional pressure, the left-arm radiation, the reproducibility, the relief — still constitutes the working definition of stable angina today. What Heberden could not know, and what took another century to establish, was that the coronary arteries running across the surface of the heart were often hard, calcified, and narrowed in these patients when examined at autopsy.[1]
The first effective therapy came not from understanding the mechanism but from observation. In 1879, William Murrell reported that nitroglycerin — the same explosive compound mixed with diatomaceous earth to make dynamite — dramatically relieved anginal attacks within minutes. Thomas Brunton had used amyl nitrite the same decade for the same purpose. Both men were right empirically before they could be right theoretically. We now know that nitrates relieve angina primarily by dilating the venous capacitance vessels, reducing the amount of blood returning to the heart, lowering left ventricular wall tension, and therefore cutting the heart's oxygen demand. Epicardial coronary dilation plays a secondary role. For nearly a century, nitrates remained the only pharmacological option. Angina was managed with rest, nitrates, and the admonition to avoid exertion.
Beta-blockers arrived in the 1960s following James Black's demonstration that blocking the adrenergic receptors on the heart would blunt the heart rate and contractility response to exercise — directly addressing the demand side of the supply-demand mismatch that produces angina. Calcium channel blockers followed in the 1970s, adding smooth muscle relaxation and additional afterload reduction. By the mid-1980s, the anti-anginal pharmacopoeia was largely complete. But the real paradigm shift was still coming. Coronary angiography — developed by Mason Sones after an inadvertent contrast injection into a right coronary artery in 1958 — made the stenoses visible, and visible stenoses became, almost inevitably, targets for intervention. Balloon angioplasty arrived in 1977 with Andreas Grüntzig's first case. The cultural presumption took hold: if the artery is blocked, open it. By the late 1990s, stenting had expanded and PCI was being performed in millions of patients annually with stable angina.
The reckoning came in 2007. The COURAGE trial enrolled 2,287 patients with stable CAD and objective ischemia and randomized them to PCI plus optimal medical therapy (OMT) versus OMT alone.[2] There was no significant difference in death or myocardial infarction at a median follow-up of 4.6 years. Then in 2020, ISCHEMIA — enrolling 5,179 patients across 37 countries with at least moderate ischemia on stress testing — confirmed and extended the COURAGE finding: a routine invasive strategy did not reduce the composite of cardiovascular death, MI, hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest.[3] Meanwhile, statins were quietly doing what stents could not. The 4S trial in 1994 showed that simvastatin reduced coronary mortality by 42% in patients with established coronary disease.[4] The lesson of the last three decades, arrived at slowly and with resistance, is that atherosclerosis is a systemic biological disease managed with medications — and that the artery that happens to be narrowest on the day of catheterization is often not the one that will cause the next event.
The heart is unlike any other organ in how it meets increased demand. Skeletal muscle, when asked to work harder, can extract more oxygen from passing blood — it uses only 30–40% of delivered oxygen at rest and can draw on large reserves during exertion. The heart, by contrast, already extracts 70–80% of the oxygen delivered to it at rest. There is essentially no reserve to tap. The only way the myocardium can get more oxygen is to receive more blood. This means coronary blood flow must increase precisely as cardiac workload rises. In a healthy heart, flow rises four- to fivefold during peak exercise through the combined effects of coronary vasodilation and increased perfusion pressure.[1]
Atherosclerotic stenosis attacks this system at its most vulnerable point. A plaque that reduces coronary artery diameter by 50% reduces the luminal cross-sectional area by 75%. At rest, this may not matter; resting flow remains adequate. During exercise, however, when flow must quadruple, the stenosis becomes a choke point. Flow cannot keep up with demand. The myocardium downstream becomes ischemic. The patient feels it as chest pressure, typically substernal, sometimes radiating to the left arm, jaw, or back, lasting 2–5 minutes, and consistently relieved by rest or sublingual nitroglycerin. This exertional pattern, reproducible and predictable, is the cardinal feature of stable angina. When a stenosis reaches 80–90% diameter reduction, resting flow may also be compromised, producing rest angina — a feature that should prompt urgent evaluation rather than outpatient management.
Atherosclerosis does not develop at random. It clusters at branch points in the major epicardial vessels — the left anterior descending artery (LAD), the right coronary artery (RCA), and the left circumflex (LCx) — where disturbed turbulent flow creates endothelial injury. The damaged endothelium loses its anticoagulant, vasodilatory, and anti-inflammatory properties. Monocytes adhere, penetrate the vessel wall, ingest oxidized low-density lipoprotein particles, and become foam cells. Over years to decades, the accumulated lipid, inflammatory cells, smooth muscle, and extracellular matrix form a plaque. In stable ischemic disease, these plaques are typically fibrocalcific — a thick fibrous cap over a lipid-rich core, calcified in older lesions, fixed in size. They narrow the lumen but do not rupture. The distinction from acute coronary syndromes is fundamental: stable angina reflects a supply limitation, not an acute thrombotic event.[5]
Two mechanistic categories explain most stable angina presentations. Demand ischemia is the classic form: a fixed stenosis limits the maximum achievable coronary flow, and any activity that raises heart rate, blood pressure, or contractility pushes demand past what supply can deliver. This is the mechanism behind exercise-induced angina with a predictable threshold. Supply ischemia involves dynamic changes in coronary tone superimposed on fixed disease: vasoconstriction triggered by endothelial dysfunction, catecholamine surges, cold air, or emotional stress. This explains why some patients have variable angina thresholds — they can walk a mile at noon but cannot walk to the mailbox on a cold morning. A third entity, coronary microvascular dysfunction, deserves separate mention. In patients whose epicardial vessels appear relatively normal on angiography but who have typical exertional angina and objective ischemia on stress testing, dysfunction of the small resistance arterioles is the culprit. This is particularly common in women and may require specialized coronary reactivity testing to diagnose. It responds incompletely to standard anti-anginal therapy.
The ischemic cascade is the predictable temporal sequence of events during a supply-demand mismatch. Perfusion falls first. Within seconds, regional wall motion abnormalities appear — the ischemic segment moves less (hypokinesis), stops moving (akinesis), or bulges outward in systole (dyskinesis). The ECG changes come next: ST-segment depression, T-wave changes. Angina symptoms arrive last — and only in roughly 70% of ischemic episodes. This sequence has direct clinical implications: imaging modalities that detect wall motion abnormalities or perfusion defects find ischemia earlier in the cascade than symptom onset or ECG changes alone, which is why stress echocardiography and nuclear perfusion imaging are more sensitive than the exercise ECG.
The Canadian Cardiovascular Society (CCS) classification provides standardized language for measuring angina severity. It is used to document treatment response, guide escalation of anti-anginal therapy, and determine when medical therapy has failed and revascularization should be reconsidered. In clinical practice, it serves as the functional outcome measure for stable angina management.[1]
| Class | Description | Clinical Examples |
|---|---|---|
| I | Ordinary activity does not cause angina. Symptoms occur only with unusually strenuous, rapid, or prolonged exertion at work or recreation. | Running, competitive sports, heavy lifting. The patient walks at a normal pace without symptoms. |
| II | Slight limitation of ordinary activity. Angina occurs with walking more than two level blocks or climbing more than one flight of stairs at a normal pace. | Walking uphill, walking after meals, walking in cold weather or wind, walking after emotional stress, walking within the first two hours after awakening. |
| III | Marked limitation of ordinary activity. Angina occurs with walking one to two level blocks or climbing one flight of stairs at a normal pace. | Slow indoor walking, dressing and grooming. Any exertion beyond minimal provokes symptoms. |
| IV | Inability to carry on any physical activity without discomfort. Angina symptoms may occur at rest. | Symptoms with minimal movement or at rest. This pattern requires urgent evaluation — resting angina distinguishes CCS IV from accelerating unstable angina. |
Do not manage the following patterns as routine stable outpatient angina. New-onset rest angina or angina lasting more than 20 minutes without relief, angina that has rapidly escalated in frequency or is provoked by progressively less exertion over days to weeks (accelerating angina), CCS class III–IV angina that is new within the past two months, angina accompanied by hemodynamic instability, diaphoresis, or new dyspnea at rest, resting ST depression or T-wave inversions, and high-risk features on stress testing — ischemia at low workload (<Bruce Stage II), ST depression >2 mm in multiple leads, or a fall in systolic blood pressure during exercise — all mandate expedited evaluation for ACS or a high-risk coronary anatomy equivalent (left main, proximal LAD, or equivalent multi-vessel disease). The shift from stable to unstable is a clinical judgment that changes urgency, antiplatelet management, and the risk of imminent MI.
The physical examination between anginal episodes is characteristically unremarkable in stable ischemic disease. What the exam provides is not a diagnosis but a risk profile: evidence of prior MI or heart failure, signs of peripheral vascular disease that confirm systemic atherosclerosis, and clues to contributing conditions like aortic stenosis, hypertrophic cardiomyopathy, or severe anemia. A classic angina history in a middle-aged man with multiple cardiovascular risk factors already carries a post-test probability of significant CAD approaching 90%; the exam refines, rather than establishes, that probability.[1]
| Finding or Test | Sensitivity | Specificity | Clinical Pearl |
|---|---|---|---|
| Classic angina history (substernal pressure, exertional onset, relieved by rest or NTG in <5 min) | ~90% for CAD in men >50 | Moderate | Positive likelihood ratio approaches 10 in high-risk patients. The history is the single most powerful diagnostic tool available. |
| Exercise ECG (Bruce protocol, ST depression ≥1 mm) | ~68–75% | ~77–85% | False-negatives are common with single-vessel disease, especially circumflex territory. False-positives with LVH, LBBB, digoxin, or baseline ST abnormalities. High-risk features (early ischemia, severe ST depression, hypotension) carry higher predictive value than the binary positive/negative result. |
| Stress echocardiography (new wall motion abnormality) | ~85% | ~88% | More sensitive than ECG alone; identifies the territory and extent of ischemia. Exercise preferred over dobutamine; add B-line assessment for exercise-induced pulmonary congestion. |
| Nuclear perfusion imaging (SPECT or PET, perfusion defect) | ~87% | ~73% | Quantifies ischemic burden. More than 10% of the LV myocardium with reversible perfusion defect has historically been used to identify patients who may derive mortality benefit from revascularization — the threshold used in ISCHEMIA enrollment criteria. |
| CT coronary angiography (CCTA) | ~95% | ~83% | Excellent negative predictive value; effectively excludes obstructive CAD in intermediate-risk patients. Best used when pre-test probability is low to intermediate and the goal is to avoid invasive angiography. CT-FFR provides functional assessment in the same scan. |
| S4 gallop on auscultation | ~30% | High | A presystolic gallop in the setting of chest pain indicates reduced LV diastolic compliance from ischemia or chronic pressure overload. Highly specific when present during or just after an anginal episode. |
| Transient MR murmur during angina | Low | Very high | A new apical systolic murmur during chest pain suggests papillary muscle ischemia from inferior or posterior wall ischemia. This is one of the most clinically significant exam findings in active ischemia. |
Stress testing is the cornerstone of evaluation after history and resting ECG. Choose the modality based on the patient's ability to exercise and on baseline ECG interpretability. Patients who can exercise and have a normal baseline ECG: standard Bruce protocol treadmill test. Patients who cannot exercise adequately: pharmacologic stress (adenosine, regadenoson for perfusion; dobutamine for echo). Patients with LBBB or ventricular pacing: nuclear or PET perfusion (not echo, which has poor specificity in these patients). Patients in whom an anatomic answer is needed first: CCTA.
Probe and views: Use the phased-array probe (cardiac preset). Obtain the parasternal long-axis (PLAX), parasternal short-axis at the mid-papillary level (PSAX), apical four-chamber (A4C), and apical two-chamber (A2C) views. In PLAX, the left ventricle should appear football-shaped with uniform wall motion — any segment that moves less, moves paradoxically, or appears thin and echobright deserves systematic characterization. The PSAX at the papillary muscle level is the most valuable view for coronary territory mapping: it simultaneously displays the anterior septum and anterior wall (LAD territory), the lateral wall (LCx territory), and the inferior wall and posterior septum (RCA territory). A wall motion abnormality in a discrete segment localizes the culprit vessel before you have seen the angiogram.[6]
Resting wall motion abnormalities as scar markers: A segment that is persistently akinetic at rest — no movement at all, not triggered by exertion — almost always represents prior myocardial infarction with established scar. When that akinetic segment is also thinned (less than 6 mm wall thickness in PSAX) and appears echobright from fibrosis replacement, it is consistent with transmural scar. Scar does not recover function after revascularization; identifying it early changes the revascularization conversation. Physician-performed point-of-care echo has been shown to detect wall motion abnormalities with accuracy approaching formal laboratory echocardiography.[7]
LV function estimation: A rapid visual estimate of ejection fraction is reliable after even brief training. A hyperdynamic ventricle — walls nearly touching in systole in PSAX — rules out significant systolic dysfunction. A severely dilated, globally hypocontractile ventricle in a patient with a multi-year angina history should prompt urgent formal echo and consideration of ischemic cardiomyopathy with chronic hibernating myocardium — a distinct entity from established scar, potentially recoverable with revascularization.
Practical POCUS applications in the stable angina clinic and emergency department go beyond diagnosing ischemia. A five-minute bedside scan provides information that changes management decisions in real time.
For foundational POCUS technique covering cardiac views, wall motion assessment, and standardized approach to the ischemic patient, see Istrail L.[6]
Laboratory evaluation in stable ischemic disease serves two purposes: identifying and quantifying the modifiable risk factors driving ongoing atherosclerosis, and detecting comorbidities that either worsen ischemia (anemia, uncontrolled thyroid disease) or complicate therapy (CKD affecting ACEi dosing, hepatic dysfunction limiting statin use). Troponin testing is the key laboratory tool when the question is whether a presentation represents stable versus unstable disease.[1]
| Test | Clinical Role & Interpretation |
|---|---|
| High-sensitivity troponin (serial) | The critical first step when a stable angina patient presents acutely is ruling out NSTEMI with serial high-sensitivity troponins (0h and 2h, or 0h and 3h per local protocol). Stable angina does not elevate troponin. A rising troponin with ischemic symptoms defines NSTEMI and changes the entire management pathway. A negative high-sensitivity troponin at 2 hours with low clinical risk effectively excludes acute MI. |
| Fasting lipid panel (LDL, HDL, non-HDL, TG) | LDL <70 mg/dL is the minimum target in established CAD; <55 mg/dL in very high-risk patients (recurrent events or multiple risk factors). Non-HDL cholesterol captures atherogenic remnant particles that LDL alone misses. Check 4–12 weeks after starting or changing therapy to confirm adherence and response. Add ezetimibe or a PCSK9 inhibitor if high-intensity statin alone is insufficient. |
| HbA1c / fasting glucose | Diabetes accelerates atherosclerosis and multiplicatively increases cardiovascular risk. Undiagnosed diabetes is common in CAD patients. In patients with diabetes and established CAD, SGLT2 inhibitors and GLP-1 receptor agonists reduce cardiovascular events independently of glucose control — these are now Class I guideline recommendations for this population. |
| CBC | Anemia increases myocardial oxygen demand and lowers the angina threshold; it can make medically controlled stable angina suddenly symptomatic. Polycythemia increases blood viscosity and prothrombotic risk. Thrombocytosis may indicate a reactive process with implications for antiplatelet therapy. |
| BMP / eGFR | CKD accelerates cardiovascular disease through multiple mechanisms (oxidative stress, hypertension, anemia, uremic toxins). eGFR is required before initiating ACE inhibitors, ARBs, or contrast for coronary angiography. Hyperkalemia from CKD may limit ACEi or aldosterone antagonist use. |
| BNP or NT-proBNP | Obtain if there is any suspicion of heart failure complicating stable angina — unexplained dyspnea, leg edema, or prior reduced EF. A markedly elevated BNP in a patient with angina history points to ischemic cardiomyopathy or HFpEF and changes management substantially. |
| Resting 12-lead ECG | Q waves confirm prior transmural MI by territory. LVH signals long-standing hypertension and adverse remodeling. LBBB precludes standard ST analysis during exercise testing (use imaging stress test). Resting ST-T changes may reflect ongoing ischemia or prior injury. A normal resting ECG does not reduce the clinical probability of significant CAD. |
Managing stable ischemic heart disease involves three simultaneous goals: eliminating the risk factors that drive atherosclerosis progression and events, relieving anginal symptoms to restore functional capacity, and — in selected patients — revascularizing when anatomy or symptom severity demands it. The ISCHEMIA trial established the cardinal principle for the vast majority of patients: optimal medical therapy accomplishes the first and second goals, and routine revascularization adds little for the third — hard cardiovascular outcomes — beyond what medications alone can achieve.[3]
| Intervention | When & How | Evidence & Key Points |
|---|---|---|
| Lifestyle modification (diet, smoking cessation, exercise, weight loss) | Foundation of all SIHD management. Mediterranean-pattern diet. Smoking cessation at any age reduces cardiovascular mortality. Supervised exercise is prescribed as “aerobic 30–60 min, 3–5 days per week” as a Class I recommendation. | Cardiac rehabilitation (supervised exercise training + risk factor management) reduces cardiovascular mortality by 26% and hospitalization by 33% in CAD patients. One of the most underutilized and evidence-based interventions available. |
| Aspirin 81 mg/day | All patients with established CAD without contraindication. Enteric-coated formulation at 81 mg. Clopidogrel 75 mg/day is an acceptable substitute when aspirin is genuinely not tolerated. | Irreversible COX-1 inhibition reduces thromboxane-mediated platelet aggregation. Meta-analyses demonstrate ~25% relative risk reduction in vascular events in secondary prevention. Higher doses offer no additional benefit and increase GI bleeding risk.[1] |
| High-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) | All patients with established CAD, indefinitely. Target LDL <70 mg/dL; <55 mg/dL in very high-risk. Check LFTs at baseline; routine monitoring not required unless symptomatic. If intolerant, try alternate-day dosing or switch agents before abandoning statin therapy. | 4S trial (1994): simvastatin reduced all-cause mortality by 30% and coronary mortality by 42% over 5.4 years in 4,444 patients with established CAD and elevated cholesterol.[4] Add ezetimibe or PCSK9 inhibitor if LDL remains above target on maximally tolerated statin. |
| ACE inhibitor or ARB | All CAD patients with hypertension, diabetes, or reduced EF (<40%). Consider in all stable CAD patients even with normal LV function and normal blood pressure. Start at low dose (lisinopril 5 mg, ramipril 5 mg); titrate to target dose over 2–4 weeks. | HOPE trial: ramipril 10 mg/day reduced the composite of MI, stroke, or CV death by 22% (RRR) in 9,541 high-risk patients, many without reduced EF or hypertension — suggesting a pleiotropic anti-atherosclerotic effect beyond blood pressure reduction.[9] |
| Beta-blocker (metoprolol succinate, bisoprolol, atenolol) | Class I in SIHD with LVEF ≤50%, ongoing angina, symptomatic arrhythmia, or hypertension. Titrate to resting HR 55–60 bpm. Anti-anginal effect: reduces HR and contractility, lowering myocardial oxygen demand. Re-evaluate the need for beta-blocker in patients >1 year post-MI with preserved EF and no angina — the 2023 guideline downgraded this to Class IIb. | First-line anti-anginal agent. Reduces angina frequency, increases exercise tolerance, and improves the angina threshold. Cardioselective agents (bisoprolol, metoprolol succinate) preferred to avoid bronchoconstriction. Common pitfall: underdosing — a patient on 25 mg of metoprolol succinate whose resting HR remains 80 bpm is not adequately beta-blocked.[10] |
| Calcium channel blockers (amlodipine, diltiazem, verapamil) | Add to beta-blocker for persistent angina; or use as monotherapy when beta-blockers are contraindicated (reactive airway disease, AV nodal block). Dihydropyridines (amlodipine) are preferred for combination with beta-blockers. Avoid combining verapamil or diltiazem with beta-blockers — excessive bradycardia and AV block risk. | As effective as beta-blockers for anginal frequency reduction. Also useful when vasospasm is suspected (Prinzmetal variant). Do not use short-acting nifedipine as monotherapy — reflex tachycardia from rapid peripheral vasodilation can worsen ischemia.[1] |
| Sublingual nitroglycerin (SL NTG 0.4 mg) | Every patient with angina receives a prescription and education. Use at onset of angina. May use prophylactically 5 min before activities likely to provoke symptoms. Repeat every 5 min ×3; if pain persists after 3 doses or 15 minutes, call 911. Instruct on upright position and hypotension risk. | Venous pooling reduces preload and LV wall tension; epicardial dilation reduces afterload and improves subendocardial perfusion. Relief within 1–5 minutes confirms ischemic etiology. Failure to respond raises concern for ACS or non-cardiac chest pain.[1] |
| Long-acting nitrates (isosorbide mononitrate extended-release) | Add for angina that persists despite beta-blocker at adequate HR control. Use eccentric dosing (e.g., 30–120 mg at 7 AM and noon, if twice-daily formulation) to allow an 8–10 hour nitrate-free interval daily and prevent tolerance. Absolutely contraindicated with phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) — fatal hypotension. | Tolerance to continuous nitrate exposure develops within 24–48 hours if a nitrate-free interval is not preserved. Eccentric dosing maintains efficacy. Headache (vasodilation) is the most common side effect and often improves after the first 1–2 weeks.[1] |
| Ranolazine (500–1000 mg twice daily) | Add as second- or third-line anti-anginal agent for refractory angina despite beta-blocker and nitrate. Does not lower heart rate or blood pressure — makes it particularly useful when patients cannot tolerate further hemodynamic agents. Avoid in severe hepatic impairment; use with caution if QTc is prolonged at baseline. Check for drug interactions (inhibits CYP3A4 metabolism). | Ranolazine inhibits the late sodium current in cardiomyocytes, reducing intracellular calcium overload during ischemia. This decreases diastolic wall tension and subendocardial ischemia without significantly affecting HR or BP. CARISA trial showed significant reduction in angina frequency and increased exercise tolerance compared to placebo in patients with chronic angina already on atenolol or amlodipine.[11] |
| PCI (percutaneous coronary intervention) | Indicated when: (1) Angina is unacceptable (CCS II–III) despite adequate medical therapy; (2) Stress testing shows a large ischemic territory and anatomy is suitable; (3) FFR ≤0.80 across a stenosis confirms hemodynamic significance. Not indicated to prevent MI or death in well-controlled stable CAD — this is what COURAGE and ISCHEMIA settled. FFR guidance (to confirm which lesions are truly flow-limiting) is mandatory before non-emergent PCI. | COURAGE (2007): PCI + OMT vs. OMT alone — no difference in death or MI at 4.6 years (n=2,287).[2] ISCHEMIA (2020): invasive strategy did not reduce the composite primary endpoint at 3.2 years (n=5,179).[3] FAME trial (2009): FFR-guided PCI reduced MACE compared to angiography-guided PCI and lowered the number of stents placed.[12] |
| CABG (coronary artery bypass grafting) | Preferred revascularization strategy when: left main disease (>50% stenosis); three-vessel disease with LVEF <50% or diabetes; two-vessel disease with proximal LAD involvement and reduced EF; anatomy not amenable to PCI. IMA-to-LAD graft has >90% patency at 10 years. | The anatomic subsets where revascularization demonstrably improves survival — left main and multi-vessel disease with LV dysfunction — are exceptions to the ISCHEMIA findings. In these patients, surgical revascularization extends life. This is not a stenting debate; it is a surgery vs. medicine debate.[1] |
| SGLT2 inhibitor or GLP-1 agonist (in patients with type 2 diabetes) | Class I recommendation in CCD patients with type 2 diabetes and high cardiovascular risk, independent of glycemic control. Empagliflozin, dapagliflozin (SGLT2); liraglutide, semaglutide (GLP-1). Start and continue regardless of whether other diabetes agents have achieved HbA1c targets. | Both drug classes reduce major adverse cardiovascular events and heart failure hospitalization in diabetic patients with established CAD, with effect sizes that exceed what glycemic control alone can explain. The 2023 AHA/ACC CCD guideline elevated these to Class I recommendations for this population.[10] |
| Recommendation — 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for Chronic Coronary Disease[10] | Class | Level | Key Point |
|---|---|---|---|
| High-intensity statin in all CCD patients; LDL target <70 mg/dL; consider <55 mg/dL in very high-risk | I | A | Add ezetimibe or PCSK9i if not at goal |
| Aspirin 75–100 mg/day in all CCD patients without contraindication | I | A | Clopidogrel as substitute |
| ACE inhibitor or ARB in CCD with HTN, DM, or EF <40% | I | A | Ramipril or equivalent |
| Beta-blocker in CCD with LVEF ≤50%, angina, arrhythmia, or HTN | I | A | Still Class I when LVEF ≤50% |
| Re-evaluate need for beta-blocker >1 year post-MI in patients with preserved EF and no other indication | IIb | B-R | Downgraded from Class I; reassess side effects |
| SGLT2 inhibitor or GLP-1 agonist in CCD with type 2 DM and high CV risk | I | A | New in 2023; CV benefit beyond glucose control |
| Sublingual NTG for acute angina relief — patient education mandatory | I | B | Prophylactic use pre-exertion emphasized |
| Supervised exercise training (cardiac rehabilitation) in CCD | I | A | Proven mortality and hospitalization benefit; chronically underutilized |
| Annual influenza vaccination in all CCD patients | I | B | Reduces cardiovascular events; independent of flu season |
| CABG for left main disease (>50%) or three-vessel disease with EF <50% | I | A | Survival benefit established; PCI does not replicate this |
| Routine PCI to reduce MI or death in stable CCD well-controlled on OMT | III | A | No benefit; avoid. Symptom benefit valid when angina is unacceptable |
| FFR guidance for revascularization decisions in non-emergent stable CAD | I | A | FFR ≤0.80 confirms hemodynamic significance; angiography alone is insufficient |
The ISCHEMIA trial result requires careful unpacking because it is widely misread in both directions. The trial enrolled 5,179 patients with at least moderate ischemia on stress testing (the majority had severe ischemia) and randomized them to a routine invasive strategy (cardiac catheterization, followed by revascularization when feasible) or a conservative strategy (medical therapy, with catheterization reserved for failure or ACS). At a median 3.2 years follow-up, the composite primary endpoint — cardiovascular death, MI, hospitalization for unstable angina, HF, or resuscitated arrest — did not differ between groups. The invasive strategy caused more early MIs (procedural) but prevented more late spontaneous MIs; the curves crossed at about two years, and by five years (ISCHEMIA-EXTEND data) there remained no survival advantage for the invasive arm.[3]
What the invasive strategy did provide: significantly faster and more complete angina relief. At one year, patients in the invasive arm had substantially better angina frequency scores and quality-of-life measures, with the largest benefit in those with the most frequent angina at baseline. By three years, this difference narrowed as conservative-arm patients either improved on medications or crossed over to revascularization. The ORBITA trial (2017) pushed this finding further: in 200 patients with severe single-vessel stenosis confirmed hemodynamically by FFR, PCI versus a sham procedure — real arterial access, heparin, catheter placement, but no stent — did not significantly improve exercise time at six weeks compared to the placebo arm.[13] Both groups got better. The implication is that PCI’s symptomatic benefit in stable single-vessel disease is partially (perhaps predominantly) a placebo effect.
The fellow-level synthesis: when a patient with CCS II–III stable angina asks about stenting, the most accurate answer is this — a stent will likely improve your symptoms faster than adjusting medications, but it will not make you live longer or prevent your next heart attack compared to optimizing medications. If your symptoms are frequent and limiting and you understand that trade-off, the procedure is reasonable. If your symptoms are well-controlled on one or two anti-anginal agents, there is no urgency and no mortality reason to proceed. The exceptions that genuinely change survival prognosis remain: left main disease, three-vessel disease with reduced EF, and proximal LAD disease with reduced EF. These anatomic subsets were excluded from or underrepresented in ISCHEMIA, and surgery for these patients is a survival intervention, not merely a quality-of-life one.
The definitive 5,179-patient trial establishing that optimal medical therapy is not inferior to an initial invasive strategy for preventing death or MI in stable CAD with moderate-to-severe ischemia. Defines current practice.
The first large trial to show that PCI plus OMT was not superior to OMT alone for death or MI in 2,287 patients with stable CAD. Challenged a generation’s assumption that opening visible stenoses improves outcomes.
First placebo-controlled (sham-procedure) trial of PCI in stable single-vessel angina confirmed by FFR. PCI did not improve exercise time versus sham at 6 weeks, revealing a substantial placebo component in its symptomatic benefit.
Established FFR-guided PCI as superior to angiography-guided PCI for selecting lesions in multivessel disease: fewer stents placed, lower MACE at 1 year. Mandated FFR use before non-emergent PCI in stable CAD.
[1] Antman EM, Loscalzo J. Chapter 267: Ischemic Heart Disease. In: Jameson JL, et al., eds. Harrison’s Principles of Internal Medicine, 20th ed. McGraw-Hill, 2018.
[2] Boden WE, O’Rourke RA, Teo KK, et al. Optimal Medical Therapy With or Without PCI for Stable Coronary Disease (COURAGE). N Engl J Med. 2007;356(15):1503–1516. PMID: 17387127. [PubMed]
[3] Maron DJ, Hochman JS, Reynolds HR, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease (ISCHEMIA). N Engl J Med. 2020;382(15):1395–1407. PMID: 32227755. [PubMed]
[4] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389. PMID: 7968073. [PubMed]
[5] Narula J, Virmani R, Narula N, Ibanez B, Fuster V. Chapter 16: Pathological Basis of Atherosclerotic Coronary Artery Disease. In: Fuster V, et al., eds. Fuster and Hurst’s The Heart, 15th ed. McGraw-Hill, 2022.
[6] Istrail L. The POCUS Textbook: Learn Point-of-Care Ultrasound of the Blood Vessels, Heart, & Lungs. ZeroGray Publishing, 2025. ISBN: 979-8-218-68730-4. [Buy on Amazon]
[7] Spencer KT, Anderson AS, Bhargava A, et al. Physician-performed point-of-care echocardiography using a laptop platform compared with physical examination in the cardiovascular patient. J Am Coll Cardiol. 2001;37(8):2013–2018. PMID: 11419879. [PubMed]
[8] Scali MC, Zagatina A, Simova I, et al. B-lines with lung ultrasound: the optimal scan technique at rest and during stress. Ultrasound Med Biol. 2017;43(11):2558–2566. PMID: 28865726. [PubMed]
[9] Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients (HOPE). N Engl J Med. 2000;342(3):145–153. PMID: 10896543. [PubMed]
[10] Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. Circulation. 2023;148(9):e9–e119. PMID: 37471501. [PubMed]
[11] Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina (CARISA). JAMA. 2004;291(3):309–316. PMID: 14734593. [PubMed]
[12] Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention (FAME). N Engl J Med. 2009;360(3):213–224. PMID: 19144937. [PubMed]
[13] Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31–40. PMID: 29103656. [PubMed]